MedPath

Goserelin

Generic Name
Goserelin
Brand Names
Zoladex
Drug Type
Small Molecule
Chemical Formula
C59H84N18O14
CAS Number
65807-02-5
Unique Ingredient Identifier
0F65R8P09N
Background

Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.

Indication

Goserelin is indicated for:

Associated Conditions
Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
Associated Therapies
Palliative Treatment
Clinical Trials
Related News

Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors

Not Applicable
Recruiting
Conditions
Advanced Malignant Solid Tumors
Interventions
Drug: Neoantigen-based DC immune preparation
First Posted Date
2023-03-01
Last Posted Date
2025-02-27
Lead Sponsor
The First Affiliated Hospital of Nanchang University
Target Recruit Count
20
Registration Number
NCT05749627
Locations
🇨🇳

First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

A Study of HH-120 Nasal Spray in Close Contacts of Those Diagnosed With COVID-19

Not Applicable
Completed
Conditions
SARS-CoV-2 Infection
COVID-19
Interventions
First Posted Date
2023-02-28
Last Posted Date
2023-02-28
Lead Sponsor
Beijing Ditan Hospital
Target Recruit Count
14
Registration Number
NCT05747677
Locations
🇨🇳

Beijing Ditan Hospital,Capital Medical University, Beijing, Beijing, China

Nivolumab with Ipilimumab Combined with TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer

Phase 1
Recruiting
Conditions
Pancreatic Cancer
Interventions
Radiation: SBRT
First Posted Date
2023-02-10
Last Posted Date
2024-10-01
Lead Sponsor
Inna Chen, MD
Target Recruit Count
20
Registration Number
NCT05721846
Locations
🇩🇰

Herlev & Gentofte University Hospital, Denmark, Herlev, Denmark

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

Phase 2
Recruiting
Conditions
Metastatic Breast Cancer
Premenopausal Breast Cancer
ER Positive Breast Cancer
Interventions
First Posted Date
2023-02-09
Last Posted Date
2024-06-10
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
42
Registration Number
NCT05720260
Locations
🇨🇳

Department of Oncology, National Taiwan University Hospital, Taipei City, Taiwan

rhBNP in Type 3 Pulmonary Hypertension

Phase 4
Conditions
Group 3 Pulmonary Hypertension
Interventions
Drug: Placebo
First Posted Date
2023-02-08
Last Posted Date
2023-10-10
Lead Sponsor
Shengjing Hospital
Target Recruit Count
72
Registration Number
NCT05716984
Locations
🇨🇳

Shengjing Hospital of China Medical University, Shenyang, Liaoning, China

🇨🇳

Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China

A Study To Assess The Efficacy and Safety of HH-120 Nasal Spray for the Treatment of Mild COVID-19

Phase 2
Completed
Conditions
COVID-19
Interventions
Drug: Placebo Comparator
First Posted Date
2023-02-06
Last Posted Date
2024-10-10
Lead Sponsor
Huahui Health
Target Recruit Count
200
Registration Number
NCT05713318
Locations
🇨🇳

Beijing Friendship Hospital,Capital Medical University, Beijing, Beijing, China

🇨🇳

The First Hospital of Jilin University, Changchun, Jilin, China

🇨🇳

Beijing Ditan Hospital, Capital Medical University, Beijing, Beijing, China

and more 13 locations

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

Completed
Conditions
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Metastatic Castration Sensitive Prostate Cancer (mCSPC)
Interventions
First Posted Date
2023-01-26
Last Posted Date
2024-04-24
Lead Sponsor
Pfizer
Target Recruit Count
1
Registration Number
NCT05701007
Locations
🇫🇮

Pfizer, Helsinki, Finland

Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)

Phase 2
Active, not recruiting
Conditions
Salivary Gland Cancer
Interventions
First Posted Date
2023-01-23
Last Posted Date
2025-05-22
Lead Sponsor
National Cancer Center Hospital East
Target Recruit Count
56
Registration Number
NCT05694819
Locations
🇯🇵

Hokkaido University Hospital, Sapporo, Hokkaido, Japan

🇯🇵

National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

🇯🇵

Tohoku University Hospital, Sendai, Miyagi, Japan

and more 9 locations

Evaluation of the Effect of Self-Assembling Peptide P11-4

Phase 1
Completed
Conditions
Dental Caries
Interventions
First Posted Date
2022-12-28
Last Posted Date
2023-01-06
Lead Sponsor
Egymedicalpedia
Target Recruit Count
30
Registration Number
NCT05667545
Locations
🇪🇬

Faculty of Dentistary - Al-Azhar University, Cairo, Egypt

A Clinical Study to Assess Preliminary Efficacy, Safety and Tolerability of HH-120 Nasal Spray in COVID-19 Patients

Not Applicable
Completed
Conditions
Coronavirus Disease 2019(COVID-19)
Interventions
First Posted Date
2022-12-21
Last Posted Date
2024-10-10
Lead Sponsor
Beijing Ditan Hospital
Target Recruit Count
111
Registration Number
NCT05659602
Locations
🇨🇳

Beijing Ditan Hospital, Capital Medical University, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy